HPV16/18 L1 VLP 疫苗可诱导交叉中和抗体，可能介导交叉保护。
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.
机构信息
HPV Immunology Laboratory, SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD 21702, USA.
出版信息
Vaccine. 2011 Mar 3;29(11):2011-4. doi: 10.1016/j.vaccine.2011.01.001. Epub 2011 Jan 15.
Abstract
Human papillomavirus (HPV) L1 VLP-based vaccines are protective against HPV vaccine-related types; however, the correlates of protection have not been defined. We observed that vaccination with Cervarix™ induced cross-neutralizing antibodies for HPV types for which evidence of vaccine efficacy has been demonstrated (HPV31/45) but not for other types (HPV52/58). In addition, HPV31/45 cross-neutralizing titers showed a significant increase with number of doses (HPV31, p<0.001; HPV45, p<0.001) and correlated with HPV16/18 neutralizing titers, respectively. These findings raise the possibility that cross-neutralizing antibodies are effectors of cross-protection observed for the HPV16/18 vaccine.
摘要
人乳头瘤病毒（HPV）L1 病毒样颗粒（VLP）疫苗可预防 HPV 疫苗相关型别；然而，保护相关因素尚未确定。我们观察到，接种佳达修（Cervarix）可诱导针对已证明具有疫苗效力的 HPV 型别（HPV31/45）的交叉中和抗体，但不针对其他型别（HPV52/58）。此外，HPV31/45 的交叉中和滴度随着剂量的增加而显著增加（HPV31，p<0.001；HPV45，p<0.001），并分别与 HPV16/18 的中和滴度相关。这些发现提示，交叉中和抗体可能是 HPV16/18 疫苗观察到的交叉保护的效应物。
相似文献
1
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.HPV16/18 L1 VLP 疫苗可诱导交叉中和抗体，可能介导交叉保护。
Vaccine. 2011 Mar 3;29(11):2011-4. doi: 10.1016/j.vaccine.2011.01.001. Epub 2011 Jan 15.
2
Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.由 Cervarix® 人乳头瘤病毒疫苗引发的交叉中和抗体显示出一系列的 Alpha-9 型间特异性。
Vaccine. 2014 Feb 26;32(10):1139-46. doi: 10.1016/j.vaccine.2014.01.008. Epub 2014 Jan 15.
3
Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.在有组织的疫苗接种计划目标人群中，二价和四价人乳头瘤病毒疫苗诱导产生的中和及交叉中和抗体滴度
Vaccine. 2014 Sep 15;32(41):5357-62. doi: 10.1016/j.vaccine.2014.07.014. Epub 2014 Jul 18.
4
Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.接种卉妍康®或加卫苗®疫苗的12至15岁女孩针对人乳头瘤病毒16型、18型、31型和45型的体液免疫反应之间的关系
PLoS One. 2015 Oct 23;10(10):e0140926. doi: 10.1371/journal.pone.0140926. eCollection 2015.
5
Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.接种佳达修或卉妍康疫苗 7 年后，对疫苗及非疫苗型 HPV 中和抗体应答的持久性。
Vaccine. 2019 Apr 24;37(18):2455-2462. doi: 10.1016/j.vaccine.2019.03.052. Epub 2019 Mar 27.
6
Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.由展示L2 17 - 36表位的佐剂重组腺相关病毒样颗粒免疫原引发的对致癌性人乳头瘤病毒的持久免疫力。
Vaccine. 2015 Oct 13;33(42):5553-5563. doi: 10.1016/j.vaccine.2015.09.005. Epub 2015 Sep 15.
7
Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.采用谷胱甘肽S-转移酶L1多重血清学检测法对HPV16/18疫苗进行免疫原性评估。
Hum Vaccin Immunother. 2014;10(10):2965-74. doi: 10.4161/21645515.2014.972811.
8
A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.一项比较佳达修（Gardasil(®)）和卉妍康（Cervarix(®)）人乳头瘤病毒疫苗在 12-15 岁少女中免疫原性的随机、观察者设盲临床试验
PLoS One. 2013 May 1;8(5):e61825. doi: 10.1371/journal.pone.0061825. Print 2013.
9
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.二价 HPV 疫苗对 HPV31 的交叉保护疫苗效力与体液免疫应答相关：来自哥斯达黎加疫苗试验的结果。
Hum Vaccin Immunother. 2013 Jul;9(7):1399-406. doi: 10.4161/hv.24340. Epub 2013 Apr 9.
10
Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.利用人乳头瘤病毒嵌合病毒样颗粒在 HPV16 L1 表面展示 31RG-1 肽可诱导小鼠产生交叉中和抗体反应。
Hum Vaccin Immunother. 2018;14(8):2025-2033. doi: 10.1080/21645515.2018.1464355. Epub 2018 May 14.
引用本文的文献
1
Reproducibility Assessment of Enzyme-Linked Immunosorbent Assays to Detect Anti-HPV16 L1-Specific IgG1, IgG3, IgA, and IgM Antibodies.用于检测抗人乳头瘤病毒16型L1特异性IgG1、IgG3、IgA和IgM抗体的酶联免疫吸附测定的重现性评估
Vaccines (Basel). 2024 Sep 27;12(10):1108. doi: 10.3390/vaccines12101108.
2
Empowering standardization of cancer vaccines through ontology: enhanced modeling and data analysis.通过本体论实现癌症疫苗标准化：增强建模和数据分析。
J Biomed Semantics. 2024 Jun 19;15(1):12. doi: 10.1186/s13326-024-00312-3.
3
Cross-neutralizing protection of vaginal and oral mucosa from HPV challenge by vaccination in a mouse model.疫苗接种对 HPV 攻击阴道和口腔黏膜的交叉中和保护作用的小鼠模型研究。
Vaccine. 2023 Jul 12;41(31):4480-4487. doi: 10.1016/j.vaccine.2023.05.057. Epub 2023 Jun 1.
4
Optimization of a protocol for the evaluation of antibody responses to human papillomavirus (HPV) vaccination in low-resource settings.优化用于评估资源匮乏环境下 HPV 疫苗接种后抗体反应的方案。
BMC Womens Health. 2022 Jun 16;22(1):234. doi: 10.1186/s12905-022-01821-y.
5
Sagacious epitope selection for vaccines, and both antibody-based therapeutics and diagnostics: tips from virology and oncology.用于疫苗、基于抗体的治疗药物和诊断方法的明智表位选择：来自病毒学和肿瘤学的提示
Antib Ther. 2022 Feb 21;5(1):63-72. doi: 10.1093/abt/tbac005. eCollection 2022 Jan.
6
Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16/18/58) in rhesus macaques.恒河猴中重组三价 HPV 疫苗（16/18/58）诱导的针对非疫苗型的交叉中和抗体效价。
Papillomavirus Res. 2020 Dec;10:100209. doi: 10.1016/j.pvr.2020.100209. Epub 2020 Nov 13.
7
Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes.针对致癌和非致癌 HPV 基因型的交叉保护 IgG 和 IgA 抗体。
Asian Pac J Cancer Prev. 2020 Sep 1;21(9):2799-2804. doi: 10.31557/APJCP.2020.21.9.2799.
8
Self-Collected Specimens Revealed a Higher Vaccine- and Non-Vaccine-Type Human Papillomavirus Prevalences in a Cross-Sectional Study in Akuse.在阿库塞的一项横断面研究中，自我采集的样本显示疫苗型和非疫苗型人乳头瘤病毒的流行率更高。
Adv Prev Med. 2020 Jan 22;2020:8343169. doi: 10.1155/2020/8343169. eCollection 2020.
9
Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules.低剂量HPV疫苗接种方案后HPV交叉中和抗体的选择性持续存在
Vaccines (Basel). 2019 Nov 28;7(4):200. doi: 10.3390/vaccines7040200.
10
Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.AS04 佐剂 HPV16/18 疫苗的疗效：哥斯达黎加疫苗和 PATRICIA 随机对照试验的汇总分析。
J Natl Cancer Inst. 2020 Aug 1;112(8):818-828. doi: 10.1093/jnci/djz222.
本文引用的文献
1
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.人乳头瘤病毒（HPV）16/18 AS04佐剂疫苗预防致癌性HPV型别所致宫颈感染和癌前病变的疗效（PATRICIA）：一项针对年轻女性的双盲随机研究的最终分析
Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6.
2
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.四价人乳头瘤病毒（HPV；6、11、16和18型）L1病毒样颗粒疫苗对16至26岁通常未感染HPV的女性因致癌性非疫苗型HPV引起的感染和疾病的影响。
J Infect Dis. 2009 Apr 1;199(7):926-35. doi: 10.1086/597307.
3
Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.接种含AS04佐剂的宫颈癌疫苗诱导产生的抗人乳头瘤病毒16型和18型抗体的长期持续性：持续抗体反应的模型
Gynecol Oncol. 2009 Dec;115(3 Suppl):S1-6. doi: 10.1016/j.ygyno.2009.01.011. Epub 2009 Feb 12.
4
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.在哥斯达黎加瓜纳卡斯特进行的一项基于社区的人乳头瘤病毒16型和18型疫苗双盲随机临床试验的原理与设计
Vaccine. 2008 Sep 2;26(37):4795-808. doi: 10.1016/j.vaccine.2008.07.002. Epub 2008 Jul 18.
5
Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.对接种疫苗女性的全身和黏膜抗HPV16及抗HPV18抗体反应的评估。
Vaccine. 2008 Jul 4;26(29-30):3608-16. doi: 10.1016/j.vaccine.2008.04.074. Epub 2008 May 19.
6
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.人乳头瘤病毒16/18 L1病毒样颗粒疫苗对已有感染的年轻女性的影响：一项随机试验。
JAMA. 2007 Aug 15;298(7):743-53. doi: 10.1001/jama.298.7.743.
7
Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.接种加德西疫苗的女性体内产生的抗体可交叉中和人乳头瘤病毒45型假病毒。
Hum Vaccin. 2007 Jul-Aug;3(4):109-15. doi: 10.4161/hv.3.4.4058. Epub 2007 Feb 24.
8
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.一种预防性四价人乳头瘤病毒6/11/16/18型L1病毒样颗粒疫苗在长达5年的随访期内具有高持续效力。
Br J Cancer. 2006 Dec 4;95(11):1459-66. doi: 10.1038/sj.bjc.6603469. Epub 2006 Nov 21.
9
Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Virology. 2006 Sep 30;353(2):451-62. doi: 10.1016/j.virol.2006.06.021. Epub 2006 Jul 24.
10
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.年轻女性预防性四价人乳头瘤病毒（6、11、16和18型）L1病毒样颗粒疫苗：一项随机双盲安慰剂对照多中心II期疗效试验。
Lancet Oncol. 2005 May;6(5):271-8. doi: 10.1016/S1470-2045(05)70101-7.
Zotero 插件